BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, September 9, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» EGL-001, a new immunocytokine with unique mechanism, demonstrates potent antitumor efficacy
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
EGL-001, a new immunocytokine with unique mechanism, demonstrates potent antitumor efficacy
May 3, 2024
No Comments
Researchers from Egle Therapeutics SAS presented the discovery of a novel immunocytokine, EGL-001, designed to selectively target tumor-infiltrating regulatory T cells (Tregs).
BioWorld Science
Conferences
American Association for Cancer Research
Cancer
Immuno-oncology